"Sample Size" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The number of units (persons, animals, patients, specified circumstances, etc.) in a population to be studied. The sample size should be big enough to have a high likelihood of detecting a true difference between two groups. (From Wassertheil-Smoller, Biostatistics and Epidemiology, 1990, p95)
Descriptor ID |
D018401
|
MeSH Number(s) |
E05.318.780.762 E05.581.500.902 N05.715.360.780.692 N06.850.520.445.762
|
Concept/Terms |
Sample Size- Sample Size
- Sample Sizes
- Size, Sample
- Sizes, Sample
|
Below are MeSH descriptors whose meaning is more general than "Sample Size".
Below are MeSH descriptors whose meaning is more specific than "Sample Size".
This graph shows the total number of publications written about "Sample Size" by people in this website by year, and whether "Sample Size" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 2 | 2 |
2006 | 0 | 1 | 1 |
2008 | 1 | 1 | 2 |
2009 | 0 | 2 | 2 |
2012 | 0 | 2 | 2 |
2013 | 0 | 1 | 1 |
2014 | 1 | 2 | 3 |
2016 | 1 | 1 | 2 |
2017 | 10 | 31 | 41 |
2018 | 3 | 29 | 32 |
2019 | 3 | 12 | 15 |
2020 | 1 | 6 | 7 |
2021 | 1 | 9 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Sample Size" by people in Profiles.
-
Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19. Am J Ther. 2021 08 06; 28(5):e616-e619.
-
Flawed ivermectin preprint highlights challenges of COVID drug studies. Nature. 2021 08; 596(7871):173-174.
-
Clinical features and predictors for patients with severe SARS-CoV-2 pneumonia at the start of the pandemic: a retrospective multicenter cohort study. BMC Infect Dis. 2021 Jul 08; 21(1):666.
-
Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. PLoS Med. 2021 07; 18(7):e1003660.
-
Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland. Nat Commun. 2021 06 08; 12(1):3455.
-
Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals. Am J Hum Genet. 2021 07 01; 108(7):1350-1355.
-
Incorporating Adult Evidence Into Pediatric Research and Practice: Bayesian Designs to Expedite Obtaining Child-Specific Evidence. JAMA. 2021 May 18; 325(19):1937-1938.
-
Salud Publica Mex. 2021 May 03; 63(3 May-Jun):444-451.
-
How COVID broke the evidence pipeline. Nature. 2021 05; 593(7858):182-185.
-
How COVID is changing the study of human behaviour. Nature. 2021 05; 593(7859):331-333.